Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWiendl, H.-
dc.contributor.authorBrandes, D.-
dc.contributor.authorCarraro, M.-
dc.contributor.authorComi, G.-
dc.contributor.authorMao-Draayer, Y.-
dc.contributor.authorIzquierdo, G.-
dc.contributor.authorKim, H. -J.-
dc.contributor.authorMeuth, S.-
dc.contributor.authorPardo, G.-
dc.contributor.authorSharrack, B.-
dc.contributor.authorTornatore, C.-
dc.contributor.authorZiemssen, T.-
dc.contributor.authorJACOBS, Andre-
dc.contributor.authorChung, L.-
dc.contributor.authorDaizadeh, N.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.identifier.citationMULTIPLE SCLEROSIS JOURNAL, 24, p. 261-262-
dc.description.sponsorshipHW: Consulting and/or speaking fees, and grant/research support (Bayer, Bayer-Schering Pharma, Biogen, Elan Corporation, Lilly, Lundbeck, Merck Serono, Novartis, Novo Nordisk, Sanofi, and Teva Neuroscience). DB: Speaker panels (Biogen, Genentech, Mallinckrodt, Novartis, Sanofi, Teva) and research support (Mallinckrodt, Novartis). MC: Speaking and consulting fees, and advisory honoraria (Biogen, Genzyme, and Mallinckrodt). GC: Consulting fees (Actelion, Bayer, Merck Serono, Novartis, Sanofi, and Teva) and lecture fees (Bayer, Biogen Dompe, Merck Serono, Novartis, Sanofi, Serono, Symposia International Foundation, and Teva). YM-D: Consulting fees and/or grant support (Acorda, Bayer, Biogen, Celgene, Chugai, EMD Serono, Genzyme, Novartis, Questor, and Teva Neuroscience); grant support (NIH NIAID Autoimmune Center of Excellence: UM1-AIII0557; NIH NINDO R01-NS080821). GI: Speaking and advisory fees (Almirall, Bayer, Biogen, Merck Serono, Novartis, Roche, Sanofi, and Teva). HJK: Consulting and/or speaking fees (Bayer, Biogen, Celltrion, Eisai, Genzyme, HanAll BioPharma, MedImmune, Merck Serono, Novartis, Teva-Handok, and UCB); research support (Genzyme, Merck Serono, Ministry of Science & ICT, Teva-Handok, and UCB); steering committee member (MedImmune); co-editor (Multiple Sclerosis Journal - Experimental, Translational, and Clinical); and associate editor (Journal of Clinical Neurology). SGM: Honoraria for lecturing, travel expenses for attending meetings, and financial research support (Almirall, Amicus Therapeutics Germany, Bayer, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, and ONO). GP: Speaking and advisory fees (Bayer, Biogen, EMD Serono, Genentech, Novartis, Sanofi, and Teva). BS: Research and travel grants, honoraria for expert advice on MS, and speaking fees (Biogen, Merck, Novartis, Roche, Sanofi, and Teva). CT: Honoraria for attending advisory boards and research funding (Bayer, Biogen, Novartis, and Sanofi). TZ: Consulting or speaking fees (Almirall, Bayer, Biogen, Merck, Novartis, Roche, Sanofi, and Teva) and grant/research support (Biogen, Novartis, Sanofi, and Teva). AJ, LC, and ND: Employees of Sanofi. BVW: Research and travel grants, honoraria for MS-expert advice, and speaking fees (Bayer-Schering, Biogen, Merck Serono, Novartis, Roche, Sanofi, and Teva). STUDY SUPPORT: Sanofi and Bayer HealthCare Pharmaceuticals.-
dc.titleNo correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateOCT 10-12, 2018-
local.bibliographicCitation.conferencename34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-
local.bibliographicCitation.conferenceplaceBerlin, GERMANY-
dc.description.notes[Wiendl, H.; Meuth, S.] Univ Munster, Munster, Germany. [Brandes, D.] Hope MS Ctr, Knoxville, TN USA. [Carraro, M.] Novant Hlth, Charlotte, NC USA. [Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy. [Mao-Draayer, Y.] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Izquierdo, G.] Virgen Macarena Univ Hosp, Seville, Spain. [Kim, H. -J.] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea. [Pardo, G.] Oklahoma Med Res Fdn, OMRF Multiple Sclerosis Ctr Excellence, 825 NE 13th St, Oklahoma City, OK 73104 USA. [Sharrack, B.] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England. [Tornatore, C.] Georgetown Univ, Med Ctr, Washington, DC 20007 USA. [Ziemssen, T.] Carl Gustav Carus Univ Hosp, Ctr Clin Neurosci, Dresden, Germany. [Jacobs, A.; Chung, L.; Daizadeh, N.] Sanofi, Cambridge, MA USA. [Van Wijmeersch, B.] Hasselt Univ, BIOMED, Rehabil & MS Ctr Overpelt, Hasselt, Belgium.-
local.type.specifiedMeeting Abstract-
item.fullcitationWiendl, H.; Brandes, D.; Carraro, M.; Comi, G.; Mao-Draayer, Y.; Izquierdo, G.; Kim, H. -J.; Meuth, S.; Pardo, G.; Sharrack, B.; Tornatore, C.; Ziemssen, T.; JACOBS, Andre; Chung, L.; Daizadeh, N. & VAN WIJMEERSCH, Bart (2018) No correlation between lymphocyte repopulation kinetics and MS disease activity following alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis. In: MULTIPLE SCLEROSIS JOURNAL, 24, p. 261-262.-
item.fulltextNo Fulltext-
item.accessRightsClosed Access-
item.contributorPardo, G.-
item.contributorCarraro, M.-
item.contributorTornatore, C.-
item.contributorJACOBS, Andre-
item.contributorMeuth, S.-
item.contributorDaizadeh, N.-
item.contributorComi, G.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorSharrack, B.-
item.contributorBrandes, D.-
item.contributorMao-Draayer, Y.-
item.contributorKim, H. -J.-
item.contributorZiemssen, T.-
item.contributorChung, L.-
item.contributorWiendl, H.-
item.contributorIzquierdo, G.-
Appears in Collections:Research publications
Show simple item record

Page view(s)

checked on Jul 6, 2022

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.